It’s only fair to share… Linustedastat CAS 2254299-48-2 MFC26H29F2N3O2 MW 453.5 g/mol FOR-6219, OG-6219, FOR 6219, OG 6219, PP3PLL7GZY, Phase 2, Endometriosis 3-[(8R,9S,13S,14S,15R,17E)-4-fluoro-17-hydroxyimino-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-15-yl]-N-(5-fluoro-2-pyridinyl)propanamide 3-[(17E)-4-fluoro-17-(hidroxiimino)estra-1,3,5(10)-trien-15β-il]-N-(5-fluoropiridin-2-il)propanamidainhibidor de la hidroxiesteroide 17-beta deshidrogenasa 1(HSD17B1) Linustedastat (developmental code names FOR-6219 and OG-6219) is a 17β-hydroxysteroid dehydrogenase 1 (17β-HSD1; HSD17B1) inhibitor which is under development for the treatment of endometriosis.[1][2][3][4][5] It is a steroidal compound derived from estrone and works by preventing the formation of the more potent estrogen estradiol from …
Tag «PHASE 2»
Iodofalan (131I)
It’s only fair to share… Iodofalan (131I) CAS 76641-05-9 MFC9H10131INO2 Molecular FormulaC9H10INO2 Molecular Weight295.09 4-(131I)iodo-L-phenylalanine (2S)-2-amino-3-(4-iodophenyl)propanoic acidradiopharmaceutical, antineoplastic, Phase 2, Glioblastoma, 606VTF676Y, 131I-TLX-101, ACD 101 Iodofalan (131I) is a radiopharmaceutical that has garnered significant attention in oncological research due to its targeted therapeutic potential. This compound, which includes the radioactive isotope Iodine-131, has been explored …
Glovadalen
It’s only fair to share… Glovadalen CAS 2576359-31-2 MF C24H27Cl2N3O3 MW 476.4 g/mol 2-(3,5-dichloro-1-methyl-1H-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(2-hydroxypropan-2-yl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl]ethan-1-one, 2-(3,5-dichloro-1-methylindazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(2-hydroxypropan-2-yl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanonedopamine D1 receptor positive allosteric modulator, Phase 2, Parkinson’s disease, UCB-0022, UCB 0022, H8T5VKH4CZ Glovadalen (developmental code name UCB-0022) is a dopamine D1 receptor positive allosteric modulator which is under development for the treatment of Parkinson’s disease.[1][2][3][4][5][6] It has been found to potentiate the capacity of dopamine to activate the D1 receptor …
Henagliflozin
It’s only fair to share… Henagliflozin, SHR-3824 , CAS 1623804-44-3 C22-H24-Cl-F-O7, 454.8756 PHASE 2 for the treatment of type 2 diabetes China 20222, approvals 2022 HengRui (Originator) Jiangsu Hengrui Medicine Co Ltd UNII-21P2M98388; 21P2M98388; Henagliflozin; SHR3824; SHR-3824; HENAGLIFLOZIN PROLINE 4IO819SW6M 570.0 g/mol C27H33ClFNO9 (1R,2S,3S,4R,5R)-5-[4-chloro-3-[(4-ethoxy-3-fluorophenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol;(2R)-pyrrolidine-2-carboxylic acid In April 2016, Jiangsu Hengrui Medicine is developing henagliflozin (phase 2 …
Tebapivat
It’s only fair to share… Tebapivat CAS 2283422-04-6 WeightAverage: 392.44Monoisotopic: 392.116778341 Chemical FormulaC18H16N8OS 10-[(6-aminopyridin-2-yl)methyl]-7-methyl-4-(1H-pyrazol-5-ylmethyl)-3-thia-5,7,10,11-tetrazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),4,11-tetraen-9-one6-[(6-aminopyridin-2-yl)methyl]-4-methyl-2-[(1H-pyrazol-3-yl)methyl]-4,6-dihydro-5H-[1,3]thiazolo[5′,4′:4,5]pyrrolo[2,3-d]pyridazin-5-one 6-[(6-aminopyridin-2-yl)methyl]-4-methyl-2-[(1H-pyrazol-3-yl)methyl]-4,6-dihydro-5H-[1,3]thiazolo[5′,4′:4,5]pyrrolo[2,3-d]pyridazin-5-one Tebapivat is under investigation in clinical trial NCT05490446 (A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-risk Myelodysplastic Syndromes (LR-MDS)). Tebapivat is an orally available activator of the red cell isoform of pyruvate kinase (PK-R; PKR), with potential to …
Alflutinib, Furmonertinib, Firmonertinib
It’s only fair to share… FIRMOMERTINIB, Furmonertinib, Alflutinib CAS 1869057-83-9 , AST 2818, UNII-A49A7A5YN4 N-[2-[[2-(Dimethylamino)ethyl]methylamino]-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-6-(2,2,2-trifluoroethoxy)-3-pyridinyl]-2-propenamide N-[2-[2-(dimethylamino)ethyl-methylamino]-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]-6-(2,2,2-trifluoroethoxy)pyridin-3-yl]prop-2-enamide C28H31F3N8O2 568.6 g/mol 2-Propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-6-(2,2,2-trifluoroethoxy)-3-pyridinyl]- Alflutinib is under investigation in clinical trial NCT03452592 (Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients With T790M). Firmonertinib is an orally available selective inhibitor of the epidermal growth …
Ervogastat
It’s only fair to share… Ervogastat CAS 2186700-33-2 Non-alcoholic Steatohepatitis (NASH) with Liver Fibrosis (FAST TRACK – U.S.) 2-[5-(3-ethoxypyridin-2-yl)oxypyridin-3-yl]-N-[(3S)-oxolan-3-yl]pyrimidine-5-carboxamide Phase IINon-alcoholic fatty liver disease; Non-alcoholic steatohepatitis Ervogastat is an experimental small-molecule drug and selective diacylglycerol O-acyltransferase 2 inhibitor developed by Pfizer for non-alcoholic steatohepatitis.[1] Its development was previously halted by the company but resumed in 2022.[2] Scheme SIDE CHAIN MAIN https://doi.org/10.1021/acs.jmedchem.2c01200 SYN …
Eclitasertib
It’s only fair to share… Eclitasertib CAS 2125450-76-0 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydropyrido[3,2-b][1,4]oxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide Molecular Weight 378.38 Formula C19H18N6O3 SAR443122, was investigated in several clinical trials to evaluate its safety and efficacy. NCT04469621 was studied in severe COVID-19 patients, while NCT05588843 is currently recruiting participants with ulcerative colitis. Additionally, NCT04781816, which was completed with results, focused on patients with cutaneous …
Davelizomib
It’s only fair to share… Davelizomib Molecular Weight 481.25 Formula C21H26BF2N3O7 CAS No. 2409841-51-4 {(4S)-2-[(1R)-1-{2-[(2S)-1-(2,4-difluorophenyl)azetidine-2- carboxamido]acetamido}-3-methylbutyl]-5-oxo-1,3,2- dioxaborolan-4-yl}acetic acid proteasome inhibitor, antineoplastic 2-[(4S)-2-[(1R)-1-[[2-[[(2S)-1-(2,4-difluorophenyl)azetidine-2-carbonyl]amino]acetyl]amino]-3-methylbutyl]-5-oxo-1,3,2-dioxaborolan-4-yl]acetic acid T3LN9U6BRF Davelizomib is proteasome inhibitor with antineoplastic effect. DAVELIZOMIB is a small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication. Multiple myeloma (MM) is a malignant proliferative …
Crisugabalin
It’s only fair to share… Crisugabalin Cas 2209104-84-5 2-[(1S,2S,3R,6S,8S)-2-(aminomethyl)-2-tricyclo[4.2.1.03,8]nonanyl]acetic acid WeightAverage: 209.289Monoisotopic: 209.141578856 Chemical FormulaC12H19NO2 Tricyclo[4.2.1.03,8]nonane-2-acetic acid, 2-(aminomethyl)-, (1S,2S,3R,6S,8S)- (1S,2S,3R,6S,8S)-2-(Aminomethyl)tricyclo[4.2.1.03,8]nonane-2-acetic acid Crisugabalin (HSK16149) is a selective GABA analog in development for the treatment of chronic pain. It has a wider therapeutic index than pregabalin, which has a similar mechanism of action. In China, it was approved in May 2024 for the treatment of …